Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784715 · ClinicalTrials.gov registry record · Phase 3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
A Phase 3 study of Breast Cancer; HER2-positive; Metastatic, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,157
- Enrollment target
- 20
- Study locations
NCT04784715 is a Phase 3 study of Breast Cancer; HER2-positive; Metastatic that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,157 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT04784715, a Phase 3 study of Breast Cancer; HER2-positive; Metastatic, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Placebo
- DRUG Trastuzumab deruxtecan
- DRUG Pertuzumab
- DRUG Taxane
Study Locations (20)
Florida
- Research Site - Miami
- Research Site - Palm Bay
- Research Site - Plantation
California
- Research Site - Glendale
- Research Site - Glendale
New York
- Research Site - New York
- Research Site - Shirley
Arizona
- Research Site - Tucson
Arkansas
- Research Site - Springdale
Colorado
- Research Site - Longmont
Georgia
- Research Site - Atlanta
Kentucky
- Research Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,157 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2029-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04784715
The ClinicalTrials.gov registry entry for NCT04784715 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer; HER2-positive; Metastatic appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT04784715 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT04784715 about?
NCT04784715 is a clinical study titled "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)". The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic s...
What is the current status of trial NCT04784715?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,157 participants. The study started on 2021-04-26. Estimated completion is 2029-12-30.
What conditions does trial NCT04784715 study?
This clinical trial studies the following conditions: Breast Cancer; HER2-positive; Metastatic.
What interventions are being tested in trial NCT04784715?
The interventions under investigation include: Trastuzumab (DRUG), Placebo (DRUG), Trastuzumab deruxtecan (DRUG), Pertuzumab (DRUG), Taxane (DRUG).
Who is sponsoring clinical trial NCT04784715?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04784715 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.